屈臣氏与阿联酋Al-Futtaim集团签特许经营协议 2025年前开100家分店
屈臣氏宣布与中东领先且业务广泛的私人企业Al-Futtaim今天(8日)宣布达成独家特许经营权协议,将集团旗下的保健美容旗舰品牌屈臣氏,引进海湾阿拉伯国家合作委员会(GCC)成员国,将是集团成立以来首次签订的特许经营权协议,以及首度将业务扩展至中东地区。
首家位於杜拜购物中心的屈臣氏旗舰店将於10月1日正式揭幕,同时网店、手机应用程式及会员计划等亦会同日推出,集团计划在2025年底前在当地开设100家分店。另外屈臣氏将於今年第四季,在杜拜节日城及阿联酋购物中心开设两家分店,并於2021年进驻沙特阿拉伯。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.